Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JAZZ PHARMACEUTICALS PLC

(JAZZ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Jazz Pharmaceuticals : Updates 2021 Full-Year Guidance Following GW Pharmaceuticals Buy

06/17/2021 | 08:52am EDT


© MT Newswires 2021
All news about JAZZ PHARMACEUTICALS PLC
07/29PHARMA MAR S A : Spain's PharmaMar sales rise on demand for cancer treatments
RE
07/29JAZZ PHARMACEUTICALS PLC : Other Events (form 8-K)
AQ
07/29Onera Health, Inc. announced that it has received €10.5 million in funding fr..
CI
07/23JAZZ PHARMACEUTICALS : RBC Boosts Price Target on Jazz Pharmaceuticals to $216 F..
MT
07/23JAZZ PHARMACEUTICALS : Rylaze Added to National Comprehensive Cancer Network Gui..
MT
07/22Jazz Pharmaceuticals plc Announces National Comprehensive Cancer Network Adds..
CI
07/22PAO GROUP, INC. INTENDS GET ITS FIRS : Paog)
AQ
07/22LIGAND PHARMACEUTICALS INCORPORATED : Partner jazz pharmaceuticals launches ryla..
AQ
07/21LIGAND PHARMACEUTICALS INCORPORATED : Pharma to Receive $7 Million in Milestone ..
MT
07/21Ligand Partner Jazz Pharmaceuticals Launches RYLAZE™ (asparaginase erwinia ch..
CI
More news
Financials (USD)
Sales 2021 3 106 M - -
Net income 2021 -172 M - -
Net Debt 2021 5 461 M - -
P/E ratio 2021 -54,2x
Yield 2021 -
Capitalization 10 336 M 10 336 M -
EV / Sales 2021 5,09x
EV / Sales 2022 3,92x
Nbr of Employees 1 940
Free-Float 97,5%
Chart JAZZ PHARMACEUTICALS PLC
Duration : Period :
Jazz Pharmaceuticals plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JAZZ PHARMACEUTICALS PLC
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 17
Last Close Price 169,52 $
Average target price 210,35 $
Spread / Average Target 24,1%
EPS Revisions
Managers and Directors
Bruce C. Cozadd Chairman & Chief Executive Officer
Daniel N. Swisher President
Renée D. Galá Chief Financial Officer & Executive Vice President
Robert Iannone Chief Medical Officer, EVP-Research & Development
Finbar Larkin Senior Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
JAZZ PHARMACEUTICALS PLC2.71%10 336
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY44.22%221 348